NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
6 trialsNCT02324296 2025-06-11
PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases
Azienda USL Reggio Emilia - IRCCS
Completed
NCT01441297 2017-08-25
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT00452634 2013-06-19
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)
National Cancer Center, Korea
Phase 2 Completed
NCT00620347 2013-06-19
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT00453167 2010-07-12
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed